ECSP066378A - "un derivado de isoxazolina como un inhibidor contra varias caspasas, un procedimiento para preparar el mismo y una composicion terapeutica para prevenir la inflamacion y la apotosis que comprende el mismo" - Google Patents
"un derivado de isoxazolina como un inhibidor contra varias caspasas, un procedimiento para preparar el mismo y una composicion terapeutica para prevenir la inflamacion y la apotosis que comprende el mismo"Info
- Publication number
- ECSP066378A ECSP066378A EC2006006378A ECSP066378A ECSP066378A EC SP066378 A ECSP066378 A EC SP066378A EC 2006006378 A EC2006006378 A EC 2006006378A EC SP066378 A ECSP066378 A EC SP066378A EC SP066378 A ECSP066378 A EC SP066378A
- Authority
- EC
- Ecuador
- Prior art keywords
- apotosis
- therapeutic composition
- prepare
- procedure
- same
- Prior art date
Links
- 102000011727 Caspases Human genes 0.000 title abstract 2
- 108010076667 Caspases Proteins 0.000 title abstract 2
- 206010061218 Inflammation Diseases 0.000 title abstract 2
- 230000004054 inflammatory process Effects 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 150000002547 isoxazolines Chemical class 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 230000006907 apoptotic process Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
La presente invención se refiere a un derivado de isoxazolina como un inhibidor contra varias caspasas, a un procedimiento para preparar el mismo y a una composición terapéutica para prevenir la inflamación y la apoptosis que comprende al mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20030059451 | 2003-08-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP066378A true ECSP066378A (es) | 2006-08-30 |
Family
ID=36102769
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2006006378A ECSP066378A (es) | 2003-08-27 | 2006-02-15 | "un derivado de isoxazolina como un inhibidor contra varias caspasas, un procedimiento para preparar el mismo y una composicion terapeutica para prevenir la inflamacion y la apotosis que comprende el mismo" |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US7557133B2 (es) |
| EP (1) | EP1660464B1 (es) |
| JP (1) | JP4503017B2 (es) |
| KR (1) | KR100594544B1 (es) |
| CN (1) | CN1842521B (es) |
| AP (1) | AP2104A (es) |
| AR (1) | AR045503A1 (es) |
| BR (1) | BRPI0413848B8 (es) |
| CA (1) | CA2535711C (es) |
| EA (1) | EA012080B1 (es) |
| EC (1) | ECSP066378A (es) |
| EG (1) | EG25751A (es) |
| IL (1) | IL173638A (es) |
| MA (1) | MA27999A1 (es) |
| MX (1) | MXPA06002267A (es) |
| MY (1) | MY162110A (es) |
| NO (1) | NO335620B1 (es) |
| NZ (1) | NZ545216A (es) |
| OA (1) | OA13244A (es) |
| PE (1) | PE20050371A1 (es) |
| TR (1) | TR200600899T2 (es) |
| TW (1) | TWI346110B (es) |
| UA (1) | UA83240C2 (es) |
| UY (1) | UY28494A1 (es) |
| WO (1) | WO2005021516A1 (es) |
| ZA (1) | ZA200601586B (es) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100774999B1 (ko) * | 2005-02-26 | 2007-11-09 | 주식회사 엘지생명과학 | 이소옥사졸린 유도체 및 그의 제조 방법 |
| US7754909B1 (en) * | 2005-04-06 | 2010-07-13 | The Florida State University Research Foundation, Inc. | Compounds and methods of arylmethylation (benzylation) as protection for alcohol groups during chemical synthesis |
| KR101299720B1 (ko) * | 2006-08-16 | 2013-08-28 | 주식회사 엘지생명과학 | 3-아미노-5-플루오로-4-디알콕시펜탄산 에스테르의 새로운제조방법 |
| KR20080042290A (ko) * | 2006-11-09 | 2008-05-15 | 주식회사 엘지생명과학 | 피리돈 구조를 포함하는 캐스파제 저해제 |
| US8288393B2 (en) | 2007-08-10 | 2012-10-16 | Nippon Soda Co., Ltd. | Nitrogen-containing heterocyclic compound and pest control agent |
| KR20090099886A (ko) * | 2008-03-18 | 2009-09-23 | 주식회사 엘지생명과학 | 캐스파제 저해제의 프로드럭 |
| EP2288615B1 (en) | 2008-05-21 | 2017-06-21 | Genesis Technologies Limited | Selective caspase inhibitors and uses thereof |
| AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
| JP5968999B2 (ja) | 2011-03-31 | 2016-08-10 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | 除草剤としておよび殺菌剤として活性な３−フェニルイソオキサゾリン−５−カルボキサミドおよび３−フェニルイソオキサゾリン−５−チオアミド |
| DK2697246T3 (en) | 2011-04-15 | 2018-05-28 | Genesis Tech Limited | SELECTIVE CYSTEIN PROTEASE INHIBITORS AND USES THEREOF |
| IN2015DN01315A (es) | 2012-09-25 | 2015-07-03 | Bayer Cropscience Ag | |
| EA026931B9 (ru) * | 2012-09-25 | 2017-11-30 | Байер Кропсайенс Аг | Гербицидно и фунгицидно действующие 5-оксизамещенные 3-фенилизоксазолин-5-карбоксамиды и 5-оксизамещенные 3-фенилизоксазолин-5-тиоамиды или их соли |
| WO2014048853A1 (de) * | 2012-09-25 | 2014-04-03 | Bayer Cropscience Ag | Herbizid und fungizid wirksame 3-heteroarylisoxazolin-5-carboxamide und 3-heteroarylisoxazolin-5-thioamide |
| JP2017095353A (ja) * | 2014-03-27 | 2017-06-01 | 日本曹達株式会社 | イソオキサゾリン−５−カルボキサミド化合物および有害生物防除剤 |
| MX2016014731A (es) | 2014-05-12 | 2017-05-04 | Conatus Pharmaceuticals Inc | Tratamiento de las complicaciones de la enfermedad cronica del higado con enfermedades de caspasa. |
| CN105753853B (zh) | 2014-12-16 | 2020-08-04 | 沈阳中化农药化工研发有限公司 | 一种含异恶唑啉的脲嘧啶类化合物及其用途 |
| WO2017079566A1 (en) | 2015-11-05 | 2017-05-11 | Conatus Pharmaceuticals, Inc. | Caspase inhibitors for use in the treatment of liver cancer |
| CN108697663A (zh) | 2015-12-31 | 2018-10-23 | 科内图斯医药公司 | 在肝病治疗中使用胱天蛋白酶抑制剂的方法 |
| BR112019005985A2 (pt) | 2016-10-05 | 2019-06-25 | Novartis Ag | composições de combinação compreendendo agonistas de fxr para tratar ou prevenir uma doença ou distúrbio fibrótico, cirrótico |
| TWI764977B (zh) * | 2017-01-23 | 2022-05-21 | 大陸商正大天晴藥業集團股份有限公司 | 作爲ｃａｓｐａｓｅ抑制劑的聯環化合物、含有其的藥物組合物及其應用 |
| SI3638665T1 (sl) | 2017-06-13 | 2021-11-30 | Bayer Aktiengesellschaft | Herbicidni 3-fenilizoksazolin-5-karboksamidi tetrahidro in dihidrofuran karboksilnih kislin in estrov |
| WO2018228986A1 (de) | 2017-06-13 | 2018-12-20 | Bayer Aktiengesellschaft | Herbizid wirksame 3-phenylisoxazolin-5-carboxamide von tetrahydro- und dihydrofurancarbonsäureamiden |
| EP3668845B1 (de) | 2017-08-17 | 2024-06-26 | Bayer Aktiengesellschaft | Herbizid wirksame 3-phenyl-5-trifluormethylisoxazolin-5-carboxamide von cyclopentylcarbonsäuren und -estern |
| AU2019210916B2 (en) | 2018-01-25 | 2023-03-02 | Bayer Aktiengesellschaft | Herbicidally active 3-phenylisoxazoline-5-carboxamides of cyclopentenyl carboxylic acid derivatives |
| AU2020238493B2 (en) | 2019-03-12 | 2025-12-18 | Bayer Aktiengesellschaft | Herbicidally active 3-phenylisoxazoline-5-carboxamides of s-containing cyclopentenyl carboxylic acid esters |
| WO2020213970A1 (ko) * | 2019-04-19 | 2020-10-22 | 주식회사 엘지화학 | 캐스파제 저해제의 프로드럭 |
| US20220227743A1 (en) * | 2019-04-30 | 2022-07-21 | Lg Chem, Ltd. | Prodrug of caspase inhibitor |
| CN113905721B (zh) * | 2019-05-31 | 2023-04-28 | 株式会社Lg化学 | 含有半胱天冬酶抑制剂前药的可注射组合物及其制备方法 |
| TWI906428B (zh) | 2020-12-10 | 2025-12-01 | 南韓商Ｌｇ化學股份有限公司 | 酸（Ｂｏｒｏｎｉｃ Ａｃｉｄ）化合物 |
| WO2022123062A1 (en) | 2020-12-11 | 2022-06-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Blocking caspase and/or fasl for preventing fatal outcome in covid-19 patients |
| CN114908028B (zh) * | 2022-04-19 | 2024-05-31 | 杭州师范大学 | 一种双相体系下化学酶法级联催化腈类化合物的一锅法合成工艺 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2738486B2 (ja) | 1992-11-20 | 1998-04-08 | ファイザー製薬株式会社 | 抗炎症剤としての新規なイソオキサゾリン類 |
| JP2818820B2 (ja) * | 1993-11-26 | 1998-10-30 | ファイザー・インク． | 抗炎症剤としての３−アリール−２−イソオキサゾリン類 |
| PL314605A1 (en) * | 1993-11-26 | 1996-09-16 | Pfizer | Isoxazolin compounds as anti-inflammatory agents |
| US5710159A (en) * | 1996-05-09 | 1998-01-20 | The Dupont Merck Pharmaceutical Company | Integrin receptor antagonists |
| IL118325A0 (en) * | 1995-05-25 | 1996-10-31 | Pont Merck And Pharmaceutical | Integrin receptor antagonists and pharmaceutical compositions containing them |
| KR100373375B1 (ko) * | 1998-04-03 | 2003-06-12 | 주식회사 엘지생명과학 | 인터루킨-1b-컨버팅효소및아포파인/cpp-32에대한저해제 |
| AU5762899A (en) * | 1999-09-17 | 2001-04-24 | Lg Chemical Ltd. | Caspase inhibitor |
| CA2388564C (en) * | 1999-09-17 | 2007-11-06 | Lg Chem Investment Ltd. | Caspase inhibitor |
-
2004
- 2004-08-24 KR KR1020040066726A patent/KR100594544B1/ko not_active Expired - Lifetime
- 2004-08-26 TR TR2006/00899T patent/TR200600899T2/xx unknown
- 2004-08-26 EG EG2004080370A patent/EG25751A/xx active
- 2004-08-26 CA CA2535711A patent/CA2535711C/en not_active Expired - Lifetime
- 2004-08-26 WO PCT/KR2004/002139 patent/WO2005021516A1/en not_active Ceased
- 2004-08-26 JP JP2006524573A patent/JP4503017B2/ja not_active Expired - Lifetime
- 2004-08-26 UA UAA200602050A patent/UA83240C2/ru unknown
- 2004-08-26 EA EA200600465A patent/EA012080B1/ru not_active IP Right Cessation
- 2004-08-26 BR BRPI0413848A patent/BRPI0413848B8/pt not_active IP Right Cessation
- 2004-08-26 CN CN2004800247028A patent/CN1842521B/zh not_active Expired - Lifetime
- 2004-08-26 US US10/568,503 patent/US7557133B2/en not_active Expired - Lifetime
- 2004-08-26 AR ARP040103065A patent/AR045503A1/es active IP Right Grant
- 2004-08-26 OA OA1200600061A patent/OA13244A/en unknown
- 2004-08-26 EP EP04774400.8A patent/EP1660464B1/en not_active Expired - Lifetime
- 2004-08-26 MX MXPA06002267A patent/MXPA06002267A/es active IP Right Grant
- 2004-08-26 NZ NZ545216A patent/NZ545216A/en not_active IP Right Cessation
- 2004-08-26 TW TW093125466A patent/TWI346110B/zh not_active IP Right Cessation
- 2004-08-26 MY MYPI20043481A patent/MY162110A/en unknown
- 2004-08-26 AP AP2006003509A patent/AP2104A/en active
- 2004-08-27 PE PE2004000822A patent/PE20050371A1/es active IP Right Grant
- 2004-08-27 UY UY28494A patent/UY28494A1/es not_active IP Right Cessation
-
2006
- 2006-02-09 IL IL173638A patent/IL173638A/en active IP Right Grant
- 2006-02-15 EC EC2006006378A patent/ECSP066378A/es unknown
- 2006-02-17 MA MA28820A patent/MA27999A1/fr unknown
- 2006-02-23 ZA ZA200601586A patent/ZA200601586B/en unknown
- 2006-03-24 NO NO20061362A patent/NO335620B1/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP066378A (es) | "un derivado de isoxazolina como un inhibidor contra varias caspasas, un procedimiento para preparar el mismo y una composicion terapeutica para prevenir la inflamacion y la apotosis que comprende el mismo" | |
| PA8554501A1 (es) | Composicion fungicida basada en derivados de arilamidina y compuestos fungicos conocidos | |
| UY28862A1 (es) | Nuevas composiciones farmaceuticas para el tratamiento de los trastornos sexuales ii | |
| SV2003001493A (es) | Indazoles substituidos, composiciones que los contienen, procedimiento de fabricacion y utilizacion | |
| AR045635A1 (es) | Empleo de agentes fungicidas par ala desinfeccion de semillas de cereales | |
| BRPI0410888A (pt) | uso de derivados de difenilmetano como inibidores de tirosinase | |
| DE602005019918D1 (de) | Formulierungen, die mitkroverkapselte etherische öle enthalten | |
| CR7877A (es) | Derivados de 4-tetrazolil-4-fenilpiperidina para tratar el dolor | |
| HN2008000792A (es) | Compuesto de cinamida biciclico | |
| MX2010005012A (es) | Composiciones para el tratamieno y prevencion de inflamacion de los parpados que comprenden un ingrediente osmoticamente activo y un vasocosntrictor. | |
| IN2015DN00502A (es) | ||
| AR052038A1 (es) | Composicion para el cuidado bucal que comprende un compuesto fenolico y vitaminas y derivados de vitaminas antioxidantes | |
| WO2007127333A3 (en) | Compositions for the treatment and prevention of eyelid swelling | |
| CL2008001755A1 (es) | Metodo para reducir efectos de deterioro asociado con pesticidas, fertilizantes o una combinacion de los mismos en una planta que comprende el tratamiento con al menos un compuesto derivado de ciclopropeno. | |
| AR109263A2 (es) | Composición que comprende moxidectina | |
| AR054939A1 (es) | Metodos para aplicar formulaciones antimicrobianas sobre alimentos | |
| CL2008002082A1 (es) | Compuestos derivados de 6-fenil-1h-imidazo[4,5-c]piridina-4-carbonitrilo, inhibidores de catepsina s y catepsina k; composicion farmaceutica; y uso en el tratamiento de osteoporosis, aterosclerosis, inflamacion, entre otras enfermedades. | |
| CR7608A (es) | Derivados de ciclotiocarbamativa como moduladores de rp y uso de los mismos para tratamiento de trastornos de la piel | |
| PA8571901A1 (es) | Nueva composicion farmaceutica | |
| PA8584501A1 (es) | Nuevos derivados de oxazol | |
| UY29723A1 (es) | Uso de arilanilidas para tratamiento de semillas | |
| PA8549401A1 (es) | Complejo que comprende factor inhibidor de osteoclastogenesis y polisacarido | |
| HN2003000104A (es) | Derivados de ciclopenteno | |
| PA8651401A1 (es) | Formas de dosificacion oral solidas que contienen una dosis baja de estradiol | |
| NI200700218A (es) | Derivados de amida como ligandos de canales iónicos y composiciones farmacéuticas y métodos para usar los mismos. |